• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    Jan 16, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ndjeka, N
    Schnippel, K
    Master, I
    Meintjes, G
    Maartens, G
    Romero, R
    Padanilam, X
    Enwerem, M
    Chotoo, S
    Singh, N
    Hughes, J
    Variava, E
    Ferreira, H
    Te Riele, J
    Ismail, N
    Mohr, E
    Bantubani, N
    Conradie, F
    Show allShow less
    Issue Date
    2018-10-25
    Submitted date
    2018-11-05
    
    Metadata
    Show full item record
    Journal
    The European Respiratory Journal
    Abstract
    Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.
    Publisher
    European Respiratory Society
    URI
    http://hdl.handle.net/10144/619311
    DOI
    10.1183/13993003.01528-2018
    PubMed ID
    30361246
    Language
    en
    Description
    We regret that this article is behind a paywall.
    ISSN
    1399-3003
    ae974a485f413a2113503eed53cd6c53
    10.1183/13993003.01528-2018
    Scopus Count
    Collections
    TB

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.